ClinicalTrials.gg
Active, not recruitingNCT05470413Updated Sep 5, 2023

Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

A Phase 3 interventional study of SHR0302 and SHR0302 in Alopecia Areata, sponsored by Reistone Biopharma Company Limited. Active, not recruiting at 31 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-05.

Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years ago, but the record still lists the study as active, not recruiting.
  • Registered 3 months after the study started (first participant enrolled Apr 2022, registered Jul 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Alopecia Areata with a site in China — 9 open to participants now, 13 under way, 6 of them phase 3. Alopecia Areata · China.

Enrollment
8th of 22
330 · median 163
Started
2022
with 3 others
Phase 3
10 of 24
4 open now
Primary completion
2023-10
later than 0 of 12 live
Registered
10th of 24
by date
Lead sponsor
2 of 24
Reistone Biopharma Company Limited

Among the 24 studies in Alopecia Areata with a site in China, this one is the 8th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2022, is one of 10 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 10th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

9 of the 24 studies in Alopecia Areata with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Alopecia Areata with a site in China, or all of them as a file.
02

Study summary

This is a multi-central, double-blind, randomized, parallel, placebo-controlled phase 3 study in adult subjects with severe alopecia areata (SALT≥50%). Approximately 330 adult patients will be enrolled into the study. Efficacy and safety of two doses of SHR0302 will be compared to placebo.

03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects with the age of ≥18 and ≤ 65 years old at the time of
  2. Have severe alopecia areata (AA), as determined by all of the followings:

    1. Clinical diagnosis of AA with no other cause of hair loss;
    2. ≥ 50% scalp involvement of alopecia (using SALT score), including alopecia totalis (AT) and alopecia universalis (AU). AT refers to scalp hair loss SALT 95-100 (both inclusive) and AU refers to scalp hair loss SALT 95-100 (both inclusive), plus facial or body hair loss.
    3. Duration of the current episode of scalp hair loss of at least 6 months and less than 8 years, and without terminal hair regrowth within 6 months prior to screening and baseline
  3. All women of and all men must be willing to use at least one highly effective method of from the signing of informed consent, throughout the duration of the study, and for 4 weeks after the last dose of drugs.
  4. Capable of providing a signed and dated informed consent form indicating the subject has been fully informed, and are willing to comply with the scheduled visits, treatment plan, laboratory testing, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Alopecia caused by other reasons, including but not limited to syphilitic alopecia, androgenetic alopecia (AGA), scarring alopecia, diffuse alopecia (manifested as diffuse hair loss), serpiginous alopecia areata (involving the temporal and occipital hairline), traction alopecia, anagen effluvium, folliculotropic mycosis fungoides (FMF), or hair loss caused by thyroid diseases.
  2. Any other active skin disease, scalp disorder, or active scalp trauma, that in the opinion of the investigator would interfere with study assessments of efficacy or safety. Subjects with shaved heads must not enter the study until the hair has grown back and is considered stable by the investigator.
  3. Have received any of the following treatment within the specified timeframes:

    •Previously systemic treated with JAK inhibitors, e.g., tofacitinib, baricitinib, upadacitinib, PF04965842, and ritlecitinib (PF-06651600).

    Exception: Patients with previous use of topical JAK inhibitors for diseases other than AA (non-scalp sites) were allowed. (discontinued 8 weeks prior to the first dose).

    • Any of the below treatments within 8 weeks prior to the first dose of drugs: topical immunotherapy, e.g., diphenylcyclopropenone (DPCP); systemic treatment to AA, e.g., oral or intravenous , cyclosporin; and intralesional therapy.
    • Any of the below treatments within 4 weeks or 5 half-lives of the drug (if known) prior to the first dose of investigational drugs, whichever is longer: topical treatments, phototherapy, cryotherapy, or any other treatment to AA.
  4. Subjects have potential active, latent, or inadequately treated infection of tubercle bacillus (TB, including, but not limited to pulmonary TB), as evidenced by any of the followings:

    • Subjects is currently being treated for active TB infection.
    • Positive QuantiFERON-TB Gold (QFT Gold test) or T-SPOT test or other interferon-gamma release assays (IGRAs) test performed within 3 months prior to/within the screening period, and those who have negative results of above tests but with clinical symptoms and/or abnormal chest X-ray that could not exclude TB infection;
    • History of either untreated or inadequately treated latent or active TB infection.

    Exception: Subject with a history of active TB who has documented evidence of appropriate treatment, has no history of re-exposure since his/her treatment was completed, and has a screening chest x-ray with no evidence of active TB may be enrolled if other entry criteria are met. Such subject would not be required to undergo the protocolspecific TB testing for QuantiFERON®-TB Gold test, or T-SPOT.TB test or other interferon-gamma release assays (IGRAs) test but must have a chest x-ray at screening.

  5. Subjects who currently have thyroid disorders (abnormal TSH levels at screening with associated abnormal fT4 or fT3 values, including hyperthyroidism and hypothyroidism), in the opinion of the investigator, pose an unacceptable risk for the patient's participation in the study.

    Note: Patients who are receiving thyroxine as replacement therapy may participate in the study, provided stable therapy has been administered for

    ≥12 weeks and TSH is within the laboratory's reference range. Patients who are receiving stable thyroxine replacement therapy who have TSH marginally outside the laboratory's normal reference range may participate if the treating physician has documented that the thyroxine replacement therapy is adequate for the patient.

  6. Subjects with a history of thrombotic disease.
  7. Subjects who may receive immunization with any live or attenuated vaccine within 4 weeks before the first dose of investigational drugs.
  8. Subjects who have participated in clinical trials of any drug or medical device within the last 1 month or 5 half-lives of the drug (whichever is longer) before screening
  9. Subjects with a history of severe neuropsychiatric disorders.
  10. Subjects with evidence of clinical laboratory abnormalities at screening that, in the opinion of the investigator, may affect the safety of subjects or the interpretation of study results:

    1. level \< 9.0 g/dL or hematocrit \< 30%.
    2. Absolute white blood cell (WBC) count \< 3.0 × 109/L (\< 3000/mm3) or (ANC) \< 1.2 × 109/L (\< 1200/mm3).
    3. Thrombocytopenia, as defined by a count of \< 100 × 109/L (\< 100,000/mm3).
    4. Total , alkaline phosphatase (ALP), (AST), or alanine aminotransferase (ALT) > 2 × . subjects with hepatic cirrhosis will be excluded.
    5. Subjects with ≤ 60 mL/min based on calculation, or patients currently undergoing regular hemodialysis or peritoneal dialysis.
  11. Screening 12-lead that demonstrates abnormalities which, in the opinion of the investigator, may affect subject safety or would interfere with study assessments if being enrolled into the study.
  12. Subject with the following concurrent or previous conditions:

    1. Clinically significant infections (e.g., requiring hospitalization or parenteral antibiotics) or opportunistic infections within 1 month prior to baseline,
    2. History of more than one episode of herpes zoster or disseminated herpes zoster (single episode) infection,
    3. Any other infections that, in the opinion of the investigator, may aggravate if the subject participate in the study,
    4. Any infection requiring antibacterial treatments within 2 weeks of randomized.
  13. Women who are pregnant or lactating or planning pregnancy while enrolled in the study. Male subjects who are planning to donate sperm during the study or within 4 weeks after the last dose of investigational drugs.
  14. History of alcohol or drug abuse with less than 6 months of abstinence prior to baseline, and unsuitable for the study in the opinion of the investigator.
  15. Subjects with a history of or allergies to JAKi, any of its ingredients, or similar compounds.
  16. Subjects with /lymphadenosis or a history of malignancies/lymphadenosis, except for adequately treated or excised non- basal cell or squamous cell carcinoma of the skin.
  17. Subjects with positive specific treponema pallidum antibody, (HIV), or /C virus:

    1. HBV positive: HBsAg positive or HBcAb positive + HBV DNA positive. NOTE: Subjects with HBcAb positive + HBV DNA negative can participate in the study.
    2. positive: HCV antibody positive + HCV RNA positive. NOTE: Subjects with HCV antibody positive+ HCV RNA negative can participate in the study.
    3. HIV positive: HIV antibody positive.
  18. Any other condition which in the opinion of the investigator would make the subject unsuitable for inclusion in the study.
  19. With evidence of clinically significant cardiovascular, mental, renal, hepatic, immune, gastrointestinal, urogenital, nervous system, musculoskeletal, cutaneous, sensory, endocrine (including uncontrolled diabetes or thyroid disease), or hematologic abnormalities. A clinically significant disease is defined as any disease that in the opinion of the investigator will endanger the safety of a subject during the participation, or the disease/condition may worsen during the study and affect the efficacy or safety analysis.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
330 participants (actual)

Study arms

  • Active comparator
    SHR0302 4 mg

    Drug:SHR0302

    Drug: SHR0302

  • Active comparator
    SHR0302 8 mg

    Drug:SHR0302

    Drug: SHR0302

  • Placebo comparator
    Placebo

    Drug: Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of subjects achieving a SALT score ≤ 20 at week 24

    Percentage of subjects achieving a SALT score ≤ 20 at week 24

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of subjects achieving a 50% improvement in SALT score (SALT50) at Week 24.

    Percentage of subjects achieving a 50% improvement in SALT score (SALT50) at Week 24.

    Time frame: 24 weeks

  2. Percentage of subjects with a SALT score ≤ 20 at Weeks 4, 8, 12, 16, 28, 36, 44, and 52.

    Percentage of subjects with a SALT score ≤ 20 at Weeks 4, 8, 12, 16, 28, 36, 44, and 52.

    Time frame: Weeks 4, 8, 12, 16, 28, 36, 44, and 52

  3. Percentage of subjects achieving a 50% improvement in SALT score (SALT50) at Weeks 4, 8, 12, 16, 28, 36, 44, and 52.

    Percentage of subjects achieving a 50% improvement in SALT score (SALT50) at Weeks 4, 8, 12, 16, 28, 36, 44, and 52.

    Time frame: Weeks 4, 8, 12, 16, 28, 36, 44, and 52.

  4. Percentage of subjects achieving a 75% improvement in SALT score (SALT75) at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Percentage of subjects achieving a 75% improvement in SALT score (SALT75) at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Time frame: Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

  5. Percentage of subjects achieving a 90% improvement in SALT score (SALT90) at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Percentage of subjects achieving a 90% improvement in SALT score (SALT90) at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Time frame: Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

  6. Absolute change from baseline in SALT score at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Absolute change from baseline in SALT score at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Time frame: Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

  7. Percentage change from baseline in SALT score at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Percentage change from baseline in SALT score at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Time frame: Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

  8. Percentage of subjects with an absolute SALT score ≤ 10 at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Percentage of subjects with an absolute SALT score ≤ 10 at Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

    Time frame: Weeks 4, 8, 12, 16, 24, 28, 36, 44, and 52.

  9. Percentage of subjects achieving "Satisfied" in Subject's Global Assessment (SGA) at Weeks 24, 36, and 52.

    Percentage of subjects achieving "Satisfied" in Subject's Global Assessment (SGA) at Weeks 24, 36, and 52.

    Time frame: Weeks 24, 36, and 52.

07

Study locations

31 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Oct 2023, 18 months after the start.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2022
First posted
Jul 22, 2022
StartActual
Apr 18, 2022
Primary completionEst.
Oct 31, 2023
CompletionEst.
Feb 15, 2024
Last update
Sep 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05470413
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Apr 18, 2022
Primary completion
Oct 31, 2023 (estimated)
Completion
Feb 15, 2024 (estimated)
Last update
Sep 5, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivarmacitinib

Start the discussion